Fresenius Kabi unveils adenosine injection in prefilled syringes
Fresenius Kabi is offering adenosine injection, in 6 mg per 2 mL and 12 mg per 4 mL single dose in Simplist ready-to-administer prefilled syringes.
Fresenius Kabi has sold 6 mg per 2 mL and 12 mg per 4 mL adenosine injection vial presentations since 2013 and 60 mg per 20 mL and 90 mg per 30 mL vial presentations since 2018.
“These new additions to our adenosine product line provide clinicians in hospitals and cardiology centers with affordable generic alternatives to care for their patients and reflect Fresenius Kabi’s significant investment in the ongoing expansion of our Simplist prefilled syringe portfolio,” Fresenius
Kabi USA president and CEO John Ducker said.
Adenosine injection is indicated intravenously for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia, including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).
Fresenius Kabi has sold 6 mg per 2 mL and 12 mg per 4 mL adenosine injection vial presentations since 2013 and 60 mg per 20 mL and 90 mg per 30 mL vial presentations since 2018.
“These new additions to our adenosine product line provide clinicians in hospitals and cardiology centers with affordable generic alternatives to care for their patients and reflect Fresenius Kabi’s significant investment in the ongoing expansion of our Simplist prefilled syringe portfolio,” Fresenius
Kabi USA president and CEO John Ducker said.
Adenosine injection is indicated intravenously for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia, including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).